May 3rd, 2024 - Press notes
Natural Killer (NK) cells, when exposed to antibody treatment used against HER2-positive breast cancer, secrete specific types of cytokines that activate the immune response against tumor cells.
Researchers have confirmed that patients with NK lymphocytes present in the tumor environment show a better response to treatment, thanks to this mechanism.
This confirms the feasibility of using cytokines secreted by NK cells as markers of response to anti-HER2 antibodies with a simple blood test. It also reaffirms various clinical trials using these lymphocytes to bolster treatment in patients with metastatic HER2-positive breast cancer.
February 23rd, 2023 - Press notes
A collaborative effort led by Dr. Anna Bigas, from the Hospital del Mar Research Institute and Josep Carreras Leukaemia Research Institute, found that the population of haematopoietic stem cells (HSC) responsible for the generation and self-renewal of the blood and immune system keeps a long-term undifferentiated state thanks to its ability to physically block its own NOTCH1 receptor through the expression of JAGGED1, a specific NOTCH activator. Authors hypothesise that the lack of this previously unknown mechanism might be the cause for the poor performance of current approaches to generate haematopoietic stem cells from induced pluripotent stem cells for regenerative medicine.
February 21st, 2024 - Press notes
This is an international collaborative work coordinated by the Hospital del Mar Research Institut and the Hospital Clínic-IDIBAPS, published in the Journal of Neurology.
This new tool may make it possible to adapt the monitoring and treatment of patients to their future evolution, opting for the most effective, but with more possible side effects in those with worse prognosis.
The exact factors behind the progression of disability in multiple sclerosis, a disease with great heterogeneity, are unknown, which is why it is so important to have tools of this type.
February 14, 2024 - Press notes
It is a monoclonal antibody with both prophylactic and therapeutic action, isolated from blood samples of a patient infected with SARS-CoV-2 during the first wave of the pandemic.
The antibody has been designed and developed by researchers from the Hospital del Mar Research Institute, the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology, and the Center for Genomic Regulation.
This new treatment has been patented pending commercial development. The results of the work have been published in Nature Communications journal.
February 9th, 2024 - Press notes
An international study has used a computational biology tool that, by analysing a multitude of biological data from multiple sclerosis patients ranging from genetic information to the whole organism, reveals the relationship between elements of different biological scales and improves our knowledge and the diagnosis of the disease.
January 30th, 2024 - Press notes
This is revealed by the largest observational study in this field carried out to date in the world. It is published in the journal Nutrients.
The work is based on data from the UK Biobank database and has made it possible to analyze information from more than 260,000 people. Its conclusions may allow a more detailed definition of future studies on omega-3 supplementation for the prevention of dementia.
The potential benefits of these fatty acids are maximal in men over 60 and in dementias other than Alzheimer's disease.
January 19th, 2024 - Press notes
The Minister of Health officially announced the cardiologist's appointment from Hospital del Mar and researcher at the Hospital del Mar Research Institute last December. Dr. Tizón replaces Dr. Josepa Mauri from Hospital Germans Trias i Pujol, who held this position for the past 8 years.
January 10, 2024 - Press notes
Functional alterations in the brains of individuals with this condition coincide with the distribution of these neurons in the same brain.
These neurons are responsible for filtering external information reaching the brain. Their functioning is altered in individuals with schizophrenia, which explains the majority of their symptoms.
This discovery is the first time that this alteration can be identified as a possible origin of schizophrenic symptoms, and it opens the door to seeking new targeted treatments with fewer patient side effects.
28 december 2023 - Press notes
19th December, 2023 - Press notes
A clinical trial carried out by Hospital del Mar, Pompeu Fabra University, the Health Research Institute of Santiago de Compostela and the Pere Virgili Health Park investigated the efficacy and safety of a medicine for outpatients with COVID-19.
The treatment acts on the replication mechanism of SARS-CoV-2, the virus responsible for the disease, and reduces the severity and duration of some of the symptoms. In addition, it can be useful to treat the different mutations detected.
Were its usefulness for treating COVID-19 confirmed, it would be one of the first drugs that could be given to primary care patients to prevent their condition from worsening and requiring hospital admission.
Parc Salut Mar
Passeig Marítim 25-29 Barcelona 08003
See location on Google maps
Phone: 93 248 30 00 · Fax: 93 248 32 54
Information request
© 2006 - 2024 Hospital del Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility
